Genetics informs precision practice in the diagnosis and management of pheochromocytoma

Hartmut P. Neumann, William Francis Young, Tobias Krauss, Jean Pierre Bayley, Francesca Schiavi, Giuseppe Opocher, Carsten C. Boedeker, Amit Tirosh, Frederic Castinetti, Juri Ruf, Dmitry Beltsevich, Martin Walz, Harald Thomas Groeben, Ernst Von Dobschuetz, Oliver Gimm, Nelson Wohllk, Marija Pfeifer, Delmar M. Lourenço, Mariola Peczkowska, Attila PatocsJoanne Ngeow, Özer Makay, Nalini S. Shah, Arthur Tischler, Helena Leijon, Gianmaria Pennelli, Karina Villar Gómez De las Heras, Thera P. Links, Birke Bausch, Charis Eng

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Although the authors of the present review have contributed to genetic discoveries in the field of pheochromocytoma research, we can legitimately ask whether these advances have led to improvements in the diagnosis and management of patients with pheochromocytoma. The answer to this question is an emphatic Yes! In the field of molecular genetics, the well-established axiom that familial (genetic) pheochromocytoma represents 10% of all cases has been overturned, with >35% of cases now attributable to germline disease-causing mutations. Furthermore, genetic pheochromocytoma can now be grouped into five different clinical presentation types in the context of the ten known susceptibility genes for pheochromocytoma-associated syndromes. We now have the tools to diagnose patients with genetic pheochromocytoma, identify germline mutation carriers and to offer gene-informed medical management including enhanced surveillance and prevention. Clinically, we now treat an entire family of tumors of the paraganglia, with the exact phenotype varying by specific gene. In terms of detection and classification, simultaneous advances in biochemical detection and imaging localization have taken place, and the histopathology of the paraganglioma tumor family has been revised by immunohistochemical-genetic classification by gene-specific antibody immunohistochemistry. Treatment options have also been substantially enriched by the application of minimally invasive and adrenal-sparing surgery. Finally and most importantly, it is now widely recognized that patients with genetic pheochromocytoma/ paraganglioma syndromes should be treated in specialized centers dedicated to the diagnosis, treatment and surveillance of this rare neoplasm.

Original languageEnglish (US)
Pages (from-to)T201-T219
JournalEndocrine-Related Cancer
Volume25
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Pheochromocytoma
Paraganglioma
Genes
Neoplasms
Germ-Line Mutation
Molecular Biology
Immunohistochemistry
Phenotype
Mutation
Antibodies
Therapeutics
Research

Keywords

  • Brown adipose tissue
  • Lipid metabolism
  • Oxidative stress
  • White adipose tissue

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Neumann, H. P., Young, W. F., Krauss, T., Bayley, J. P., Schiavi, F., Opocher, G., ... Eng, C. (2018). Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocrine-Related Cancer, 25(8), T201-T219. https://doi.org/10.1530/ERC-18-0085

Genetics informs precision practice in the diagnosis and management of pheochromocytoma. / Neumann, Hartmut P.; Young, William Francis; Krauss, Tobias; Bayley, Jean Pierre; Schiavi, Francesca; Opocher, Giuseppe; Boedeker, Carsten C.; Tirosh, Amit; Castinetti, Frederic; Ruf, Juri; Beltsevich, Dmitry; Walz, Martin; Groeben, Harald Thomas; Von Dobschuetz, Ernst; Gimm, Oliver; Wohllk, Nelson; Pfeifer, Marija; Lourenço, Delmar M.; Peczkowska, Mariola; Patocs, Attila; Ngeow, Joanne; Makay, Özer; Shah, Nalini S.; Tischler, Arthur; Leijon, Helena; Pennelli, Gianmaria; De las Heras, Karina Villar Gómez; Links, Thera P.; Bausch, Birke; Eng, Charis.

In: Endocrine-Related Cancer, Vol. 25, No. 8, 01.08.2018, p. T201-T219.

Research output: Contribution to journalReview article

Neumann, HP, Young, WF, Krauss, T, Bayley, JP, Schiavi, F, Opocher, G, Boedeker, CC, Tirosh, A, Castinetti, F, Ruf, J, Beltsevich, D, Walz, M, Groeben, HT, Von Dobschuetz, E, Gimm, O, Wohllk, N, Pfeifer, M, Lourenço, DM, Peczkowska, M, Patocs, A, Ngeow, J, Makay, Ö, Shah, NS, Tischler, A, Leijon, H, Pennelli, G, De las Heras, KVG, Links, TP, Bausch, B & Eng, C 2018, 'Genetics informs precision practice in the diagnosis and management of pheochromocytoma', Endocrine-Related Cancer, vol. 25, no. 8, pp. T201-T219. https://doi.org/10.1530/ERC-18-0085
Neumann, Hartmut P. ; Young, William Francis ; Krauss, Tobias ; Bayley, Jean Pierre ; Schiavi, Francesca ; Opocher, Giuseppe ; Boedeker, Carsten C. ; Tirosh, Amit ; Castinetti, Frederic ; Ruf, Juri ; Beltsevich, Dmitry ; Walz, Martin ; Groeben, Harald Thomas ; Von Dobschuetz, Ernst ; Gimm, Oliver ; Wohllk, Nelson ; Pfeifer, Marija ; Lourenço, Delmar M. ; Peczkowska, Mariola ; Patocs, Attila ; Ngeow, Joanne ; Makay, Özer ; Shah, Nalini S. ; Tischler, Arthur ; Leijon, Helena ; Pennelli, Gianmaria ; De las Heras, Karina Villar Gómez ; Links, Thera P. ; Bausch, Birke ; Eng, Charis. / Genetics informs precision practice in the diagnosis and management of pheochromocytoma. In: Endocrine-Related Cancer. 2018 ; Vol. 25, No. 8. pp. T201-T219.
@article{5086fb38f5314e1c924ee1a7456a507f,
title = "Genetics informs precision practice in the diagnosis and management of pheochromocytoma",
abstract = "Although the authors of the present review have contributed to genetic discoveries in the field of pheochromocytoma research, we can legitimately ask whether these advances have led to improvements in the diagnosis and management of patients with pheochromocytoma. The answer to this question is an emphatic Yes! In the field of molecular genetics, the well-established axiom that familial (genetic) pheochromocytoma represents 10{\%} of all cases has been overturned, with >35{\%} of cases now attributable to germline disease-causing mutations. Furthermore, genetic pheochromocytoma can now be grouped into five different clinical presentation types in the context of the ten known susceptibility genes for pheochromocytoma-associated syndromes. We now have the tools to diagnose patients with genetic pheochromocytoma, identify germline mutation carriers and to offer gene-informed medical management including enhanced surveillance and prevention. Clinically, we now treat an entire family of tumors of the paraganglia, with the exact phenotype varying by specific gene. In terms of detection and classification, simultaneous advances in biochemical detection and imaging localization have taken place, and the histopathology of the paraganglioma tumor family has been revised by immunohistochemical-genetic classification by gene-specific antibody immunohistochemistry. Treatment options have also been substantially enriched by the application of minimally invasive and adrenal-sparing surgery. Finally and most importantly, it is now widely recognized that patients with genetic pheochromocytoma/ paraganglioma syndromes should be treated in specialized centers dedicated to the diagnosis, treatment and surveillance of this rare neoplasm.",
keywords = "Brown adipose tissue, Lipid metabolism, Oxidative stress, White adipose tissue",
author = "Neumann, {Hartmut P.} and Young, {William Francis} and Tobias Krauss and Bayley, {Jean Pierre} and Francesca Schiavi and Giuseppe Opocher and Boedeker, {Carsten C.} and Amit Tirosh and Frederic Castinetti and Juri Ruf and Dmitry Beltsevich and Martin Walz and Groeben, {Harald Thomas} and {Von Dobschuetz}, Ernst and Oliver Gimm and Nelson Wohllk and Marija Pfeifer and Louren{\cc}o, {Delmar M.} and Mariola Peczkowska and Attila Patocs and Joanne Ngeow and {\"O}zer Makay and Shah, {Nalini S.} and Arthur Tischler and Helena Leijon and Gianmaria Pennelli and {De las Heras}, {Karina Villar G{\'o}mez} and Links, {Thera P.} and Birke Bausch and Charis Eng",
year = "2018",
month = "8",
day = "1",
doi = "10.1530/ERC-18-0085",
language = "English (US)",
volume = "25",
pages = "T201--T219",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "8",

}

TY - JOUR

T1 - Genetics informs precision practice in the diagnosis and management of pheochromocytoma

AU - Neumann, Hartmut P.

AU - Young, William Francis

AU - Krauss, Tobias

AU - Bayley, Jean Pierre

AU - Schiavi, Francesca

AU - Opocher, Giuseppe

AU - Boedeker, Carsten C.

AU - Tirosh, Amit

AU - Castinetti, Frederic

AU - Ruf, Juri

AU - Beltsevich, Dmitry

AU - Walz, Martin

AU - Groeben, Harald Thomas

AU - Von Dobschuetz, Ernst

AU - Gimm, Oliver

AU - Wohllk, Nelson

AU - Pfeifer, Marija

AU - Lourenço, Delmar M.

AU - Peczkowska, Mariola

AU - Patocs, Attila

AU - Ngeow, Joanne

AU - Makay, Özer

AU - Shah, Nalini S.

AU - Tischler, Arthur

AU - Leijon, Helena

AU - Pennelli, Gianmaria

AU - De las Heras, Karina Villar Gómez

AU - Links, Thera P.

AU - Bausch, Birke

AU - Eng, Charis

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Although the authors of the present review have contributed to genetic discoveries in the field of pheochromocytoma research, we can legitimately ask whether these advances have led to improvements in the diagnosis and management of patients with pheochromocytoma. The answer to this question is an emphatic Yes! In the field of molecular genetics, the well-established axiom that familial (genetic) pheochromocytoma represents 10% of all cases has been overturned, with >35% of cases now attributable to germline disease-causing mutations. Furthermore, genetic pheochromocytoma can now be grouped into five different clinical presentation types in the context of the ten known susceptibility genes for pheochromocytoma-associated syndromes. We now have the tools to diagnose patients with genetic pheochromocytoma, identify germline mutation carriers and to offer gene-informed medical management including enhanced surveillance and prevention. Clinically, we now treat an entire family of tumors of the paraganglia, with the exact phenotype varying by specific gene. In terms of detection and classification, simultaneous advances in biochemical detection and imaging localization have taken place, and the histopathology of the paraganglioma tumor family has been revised by immunohistochemical-genetic classification by gene-specific antibody immunohistochemistry. Treatment options have also been substantially enriched by the application of minimally invasive and adrenal-sparing surgery. Finally and most importantly, it is now widely recognized that patients with genetic pheochromocytoma/ paraganglioma syndromes should be treated in specialized centers dedicated to the diagnosis, treatment and surveillance of this rare neoplasm.

AB - Although the authors of the present review have contributed to genetic discoveries in the field of pheochromocytoma research, we can legitimately ask whether these advances have led to improvements in the diagnosis and management of patients with pheochromocytoma. The answer to this question is an emphatic Yes! In the field of molecular genetics, the well-established axiom that familial (genetic) pheochromocytoma represents 10% of all cases has been overturned, with >35% of cases now attributable to germline disease-causing mutations. Furthermore, genetic pheochromocytoma can now be grouped into five different clinical presentation types in the context of the ten known susceptibility genes for pheochromocytoma-associated syndromes. We now have the tools to diagnose patients with genetic pheochromocytoma, identify germline mutation carriers and to offer gene-informed medical management including enhanced surveillance and prevention. Clinically, we now treat an entire family of tumors of the paraganglia, with the exact phenotype varying by specific gene. In terms of detection and classification, simultaneous advances in biochemical detection and imaging localization have taken place, and the histopathology of the paraganglioma tumor family has been revised by immunohistochemical-genetic classification by gene-specific antibody immunohistochemistry. Treatment options have also been substantially enriched by the application of minimally invasive and adrenal-sparing surgery. Finally and most importantly, it is now widely recognized that patients with genetic pheochromocytoma/ paraganglioma syndromes should be treated in specialized centers dedicated to the diagnosis, treatment and surveillance of this rare neoplasm.

KW - Brown adipose tissue

KW - Lipid metabolism

KW - Oxidative stress

KW - White adipose tissue

UR - http://www.scopus.com/inward/record.url?scp=85051241960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051241960&partnerID=8YFLogxK

U2 - 10.1530/ERC-18-0085

DO - 10.1530/ERC-18-0085

M3 - Review article

C2 - 29794110

AN - SCOPUS:85051241960

VL - 25

SP - T201-T219

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 8

ER -